Kissei Pharmaceutical (4547) Q4 2026 earnings summary

Executive summary

• Net sales reached ¥97,406 million, up 10.3% year-over-year, driven by growth in pharmaceuticals and information services, setting a new record high.

• Operating and ordinary losses were recorded due to increased R&D, SG&A, and cost of sales, despite higher sales.

• Net income attributable to owners of parent rose 15.2% to ¥13,779 million, aided by extraordinary gains from investment securities sales.

• Comprehensive income surged to ¥31,399 million from a prior year loss.

• Domestic pharmaceutical sales grew 5.9% year-over-year, with strong performance from Beova, TAVNEOS, KORSUVA, and TAVALISSE.

Financial highlights

• Gross profit increased 4.0% year-over-year to ¥45,818 million, while cost of sales rose 16.5%.

• R&D expenses surged 74.7% year-over-year to ¥22,521 million, reflecting in-licensing and clinical development activities.

• Operating loss was ¥2,927 million and ordinary loss ¥1,162 million, both negative compared to prior year profits.

• Extraordinary income included ¥17,044 million from sale of investment securities, contributing to higher net income.

• Cash and cash equivalents at year-end were ¥53,971 million, up 12.1% year-over-year.

Outlook and guidance

• Net sales for the next fiscal year are forecast at ¥95,700 million, down 1.8% due to a decline in information services, despite a 5.2% rise in domestic pharmaceuticals.

• Operating and ordinary profits are expected to turn positive, with net income projected to increase 5.2% to ¥14,500 million.

• R&D expenses are planned to decrease 26.7% to ¥16,500 million.

• Full-year dividend forecast is ¥170 per share, including commemorative dividends.